# Sub-Q Bionics Targets $5M Seed Round After Pre-Seed Close and Mayo Clinic Partnership

> financing · REPORTED · 2026-04-14

Following its $1.5 million pre-seed close and Mayo Clinic licensing deal, Sub-Q Bionics is actively targeting a $5 million seed round to fund its next development phase focused on women who have survived breast cancer and live with lymphedema. CEO Jordan Pollack has described the patient mission as enabling women with lymphedema to thrive, not just survive.

About Sub-Q Bionics: Sub-Q Bionics develops an implantable lymphatic drainage system intended to permanently manage lymphedema in breast cancer survivors by replicating lymphatic circulation beneath the skin.

- Company: Sub-Q Bionics
- Sector: medical devices
- Primary source: https://med-tech.world/news/sub-q-bionics-seed-round-lymphedema/

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.